Impact of SHMT1 polymorphism on the clinical outcome of patients with metastatic colorectal cancer treated with first-line FOLFIRI+bevacizumab

Pharmacogenetics and Genomics

Volumn 22, Issue 1, 2012, Pages 69-72

  Budai, Barna ^a   Komlósi, Viktor ^b   Adleff, Vilmos ^a   Pap, Éva ^a   Réti, Andrea ^a   Nagy, Tünde ^a   Kralovánszky, Judit ^a   Láng, István ^a   Hitre, Erika ^a  

^a NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

^b SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

first line chemotherapy; hypertension; metastatic colorectal cancer; polymorphism; SHMT1 C1420T; survival

Indexed keywords

BEVACIZUMAB; CELL DNA; CREATININE; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; FOLINIC ACID; HOMOCYSTEINE; IRINOTECAN; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); METHYLTRANSFERASE; SERINE HYDROXYMETHYLTRANSFERASE 1; THYMIDYLATE SYNTHASE; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; AMINO ACID BLOOD LEVEL; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; COLORECTAL CANCER; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DNA EXTRACTION; DRUG DOSE REDUCTION; DRUG EFFICACY; ENZYME ACTIVITY; GENOTYPE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; METASTATIC COLORECTAL CANCER; OVERALL SURVIVAL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SINGLE NUCLEOTIDE POLYMORPHISM; TANDEM REPEAT; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 83655184792     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e32834d8376     Document Type: Article

References (13)

1. Funke S, Brenner H, Chang-Claude J. Pharmacogenetics in colorectal cancer: a systematic review. Pharmacogenomics 2008; 9:1079-1099.
2. Atta HM, El-Rehani MA, Raheim SA, Galal AMF. Lowering homocysteine decreases levels and expression of VEGF(165) and endostatin. J Surg Res 2008; 146:202-210. (Pubitemid 351484133)
3. Rouits E, Charasson V, Pétain A, Boisdron-Celle M, Delord J-P, Fonck M, et al. Pharmacokinetic and pharmacogenetic determinants of the activity and toxicity of irinotecan in metastatic colorectal cancer patients. Br J Cancer 2008; 99:1239-1245.
4. Ayerden Ebinç F, Haksun E, Ulver DB, Kotz E, Erten Y, Altok KR, et al. The relationship between vascular endothelial growth factor (VEGF) and microalbuminuria in patients with essential hypertension. Intern Med 2008; 47:1511-1516.
5. Scartozzi M, Galizia E, Chiorrini S, Giampieri R, Berardi R, Pierantoni C, et al. Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. Ann Oncol 2009; 20:227-230.
6. Komlósi V, Hitre E, Pap E, Adleff V, Réti A, Székely E, et al. SHMT1 1420 and MTHFR 677 variants are associated with rectal but not colon cancer. BMC Cancer 2010; 10:525.
7. Réti A, Barna G, Pap E, Adleff V, Komlósi VL, Jeney A, et al. Enhancement of 5-fluorouracil efficacy on high COX-2 expressing HCA-7 cells by low dose indomethacin and NS-398 but not on low COX-2 expressing HT-29 cells. Pathol Oncol Res 2009; 15:335-344.
8. Hitre E, Budai B, Adleff V, Czeglédi F, Horváth Zs, Gyergyay F, et al. Influence of thymidylate synthase gene polymorphisms on the survival of colorectal cancer patients receiving adjuvant 5-fluorouracil. Pharmacogenet Genomics 2005; 15:723-730. (Pubitemid 41345324)
9. Hitre E, Budai B, Adleff V, Komlósi V, Czeglédi F, Pap É, et al. Comparison of first-line deGramont, FOLFIRI and bevacizumab + FOLFIRI treatments in case of different genotypes of metastatic colorectal cancer patients. Magy Onkol 2009; 53 (Suppl):47.
10. Formica V, Palmirotta R, Del Monte G, Savonarola A, Ludovici G, De Marchis ML, et al. Predictive value of VEGF gene polymorphisms for metastatic colorectal cancer patients receiving first-line treatment including fluorouracil, irinotecan, and bevacizumab. Int J Colorectal Dis 2011; 26:143-151.
11. Hoskins JM, Goldberg RM, Qu P, Ibrahim JG, McLeod HL. UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. J Natl Cancer Inst 2007; 99:1290-1295. (Pubitemid 47394168)
12. Palomaki GE, Bradley LA, Douglas MP, Kolor K, Dotson WD. Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based review. Genet Med 2009; 11:21-34.
13. Martinez-Balibrea E, Abad A, Mart́nez-Cardús A, Ginés A, Valladares M, Navarro M, et al. UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy. Br J Cancer 2010; 103:581-589.